The first known lawsuit has now been filed against the makers of Dupixent (dupilumab), alleging that the popular eczema and asthma drug caused or accelerated a deadly form of lymphoma.
Filed in federal court in Tennessee, the case represents a pivotal moment in the litigation against Regeneron Pharmaceuticals and Sanofi-Aventis, the drug’s manufacturers. For patients and families who have long suspected something was wrong, this filing is both validating and deeply concerning.
What the Dupixent Lawsuit Claims
According to the complaint, the plaintiff’s mother developed T-cell lymphoma shortly after starting Dupixent and died months later. The lawsuit alleges that the drug’s manufacturers:
- Failed to warn doctors and patients of the risk that Dupixent could cause or accelerate T-cell lymphoma.
- Negligently manufactured, distributed, and marketed Dupixent despite growing evidence linking Dupixent to peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).
While this is the first Dupixent case of its kind, attorneys and medical experts expect additional lawsuits to follow as awareness spreads and more patients come forward. It’s important to understand that this case holds the drug manufacturers — not the treating doctors — responsible for failing to warn about potential cancer risks.
Why This First Dupixent Case Matters
This first Dupixent filing matters most of all to the family of Cynthia Marie Hyde, who passed away following her Dupixent use, and who are seeking justice in this lawsuit. But it is also important for other patients and families affected by Dupixent use:
- It confirms what many suspected: This is no longer theoretical. There is now a concrete legal claim seeking to hold Dupixent’s manufacturers accountable.
- It may set the tone for future litigation: This case could serve as a legal blueprint for how others frame their claims, like what evidence is considered, how liability theories are structured, and how causation is argued.
- It can trigger broader discovery and scrutiny: Through court proceedings, plaintiffs may gain access to internal documents, research data, clinical trial files, and communications from manufacturers. These are all critical documents that are not publicly available now.
- It draws attention from regulators and media: A high-profile lawsuit raises regulatory pressure and public awareness, which may influence FDA action, label changes, or further investigations.
Even if this case is only the beginning, it represents a turning point in the conversation around Dupixent and patient safety.
What We Know About Dupixent and Lymphoma So Far
Dupixent is designed to reduce inflammation by blocking two key immune pathways: IL-4 and IL-13. For most patients, that means relief from eczema or asthma. But for some, it may also mean suppressed immune surveillance — the body’s natural defense against abnormal cell growth.
Recent medical reports and studies have raised red flags. Several published case reports describe patients developing CTCL or mycosis fungoides after starting Dupixent and a 2025 study found a 350% increase in CTCL risk among Dupixent users compared to those on other therapies. In some cases, doctors tragically mistook the developing cancer for worsening eczema, delaying diagnosis and treatment, putting the patient’s health at greater risk.
Despite extensive scientific evidence, Dupixent’s label does not currently warn about the risk of T-cell lymphoma. The FDA has not yet confirmed a direct causal link, but its adverse event database includes dozens of similar reports.
What Patients and Families Should Do Now
If you or your loved one has taken Dupixent and developed unexplained or worsening skin symptoms, don’t wait for answers. Here are proactive steps you can take today:
- Get a thorough medical evaluation. If you notice persistent rashes, skin thickening, night sweats, or swollen lymph nodes, ask your doctor to consider lymphoma as a possible cause.
- Request a biopsy and pathology review. In some cases, early cancer may be misdiagnosed as eczema.
- Keep detailed medical records. Document when you started taking Dupixent, when symptoms appeared, and all follow-up visits and test results.
- Report your experience. You or your healthcare provider can submit an adverse event report through the FDA’s MedWatch program.
- Consult an attorney experienced in drug litigation. Morris James offers a free, no-risk consultation to discuss your options and protect your rights before deadlines expire. If you choose to pursue litigation, we will take your case on a contingency basis, meaning you don’t pay any fees unless we win.
With the first Dupixent case now filed, we expect more families to step forward in the coming months to seek justice for their loved ones.
If You Believe Dupixent Caused Harm
You don’t have to face this uncertainty alone. Our Dupixent attorneys are actively reviewing Dupixent-related lymphoma cases and can help you understand your options at no cost.
